Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs).
Palmieri G, Merola G, Federico P, Petillo L, Marino M, Lalle M, Milella M, Ceribelli A, Montella L, Merola C, Del Prete S, Bergaglio M, De Placido S, Di Lorenzo G. Palmieri G, et al. Among authors: federico p. Ann Oncol. 2010 Jun;21(6):1168-1172. doi: 10.1093/annonc/mdp483. Epub 2009 Oct 30. Ann Oncol. 2010. PMID: 19880439 Free article. Clinical Trial.
Efficacy of rituximab in gastric diffuse large B cell lymphoma patients.
Leopardo D, Di Lorenzo G, De Renzo A, Federico P, Luponio S, Buonerba C, Matano E, Merola G, Imbimbo M, Montesarchio E, Rea A, Merola MC, De Placido S, Palmieri G. Leopardo D, et al. Among authors: federico p. World J Gastroenterol. 2010 May 28;16(20):2526-30. doi: 10.3748/wjg.v16.i20.2526. World J Gastroenterol. 2010. PMID: 20503452 Free PMC article.
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V. Di Lorenzo G, et al. Among authors: federico p. Eur Urol. 2010 Dec;58(6):906-11. doi: 10.1016/j.eururo.2010.09.008. Epub 2010 Sep 24. Eur Urol. 2010. PMID: 20884115
A comprehensive outlook on intracerebral therapy of malignant gliomas.
Buonerba C, Di Lorenzo G, Marinelli A, Federico P, Palmieri G, Imbimbo M, Conti P, Peluso G, De Placido S, Sampson JH. Buonerba C, et al. Among authors: federico p. Crit Rev Oncol Hematol. 2011 Oct;80(1):54-68. doi: 10.1016/j.critrevonc.2010.09.001. Epub 2010 Oct 2. Crit Rev Oncol Hematol. 2011. PMID: 20888252 Review.
Is hypogammaglobulinemia a constant feature in Good's syndrome?
Federico P, Imbimbo M, Buonerba C, Damiano V, Marciano R, Serpico D, Di Lorenzo G, Palmieri G. Federico P, et al. Int J Immunopathol Pharmacol. 2010 Oct-Dec;23(4):1275-9. doi: 10.1177/039463201002300434. Int J Immunopathol Pharmacol. 2010. PMID: 21244779 Free article.
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G. Buonerba C, et al. Among authors: federico p. Cancer Chemother Pharmacol. 2011 Jun;67(6):1455-61. doi: 10.1007/s00280-011-1594-z. Epub 2011 Mar 2. Cancer Chemother Pharmacol. 2011. PMID: 21365219 Clinical Trial.
Imatinib mesylate in thymic epithelial malignancies.
Palmieri G, Marino M, Buonerba C, Federico P, Conti S, Milella M, Petillo L, Evoli A, Lalle M, Ceribelli A, Merola G, Matano E, Sioletic S, De Placido S, Di Lorenzo G, Damiano V. Palmieri G, et al. Among authors: federico p. Cancer Chemother Pharmacol. 2012 Feb;69(2):309-15. doi: 10.1007/s00280-011-1690-0. Epub 2011 Jun 28. Cancer Chemother Pharmacol. 2012. PMID: 21710245 Clinical Trial.
240 results